GoodRx Holdings, Inc.

NASDAQ:GDRX

Medical - Healthcare Information Services

Healthcare
$3.36 +1.72%

+$0.05 today

Market cap
$1.15B
Beta
1.61
P/E (TTM)
44.0
EPS (TTM)
$0.06
52W Low $1.77High $5.81

Volume 0.66M

Average 1.61M

GDRX Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

GoodRx Holdings, Inc.NASDAQ: GDRX

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue growth accelerates

Q1 FY2026 cost of revenue of $41.95M rose 213.9% year over year, ahead of the +115.7% change in trailing-twelve-month cost of revenue. Sequentially, it rose 140.2% from the prior quarter. Over 3 fiscal years it compounded at -4.0% a year.

Context

  • Cost of revenue amounted to 7.2% of revenue in FY2025, up 1.1 pp from a year earlier.
  • Cost of revenue increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +213.9% holds above the trailing-twelve-month pace of +115.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$41.95M+140.2% QoQ
Last fiscal yearDec 2025
$57.6M+19.5% YoY
LTMMar 2026
$105.91M+115.7% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+213.9%——
1 year+19.5%——
3-year CAGR-4.0%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
57.6M USD
Year-over-year change
+19.5%
4-year CAGR
+5.4%

Cost of Revenue vs competitors

How GDRX compares with its peers on the latest reported figures

  • GDRX's LTM Mar 2026 cost of revenue of $105.91M is the 3rd highest of the 4 companies compared; the peer median is $119.38M.
  • Its year-over-year change of +115.7% is the highest of 4, against a peer median of +10.1%.
  • Cost of revenue amounts to 13.4% of revenue for GDRX, versus a peer median of 34.4%.
GDRX Competitors Peer median
Cost of Revenue for GDRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TDOCTeladoc Health, Inc.LTM Mar 2026$864.58M +14.7%+1.2%34.4%
AMWLAmerican Well CorporationLTM Mar 2026$119.38M -18.1%-10.1%50.3%
GDRXGoodRx Holdings, Inc.LTM Mar 2026$105.91M +115.7%-4.0%13.4%
LFMDLifeMD, Inc.LTM Mar 2026$30.96M +10.1%+28.2%14.1%
Peer median (excluding GDRX) $119.38M+10.1%+1.2%34.4%

Competitors are the stored peer set for GDRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue745.42M766.55M750.27M792.32M796.85M
Cost of Revenue46.72M65.08M66.93M48.22M57.6M
Gross Profit698.71M701.48M683.34M744.11M739.26M
Gross Margin93.7%91.5%91.1%93.9%92.8%
Research & Development125.86M143.14M135.84M123.75M121.03M
Selling, General & Admin524.9M502.42M466.84M484.98M445.52M
Operating Expenses685.3M699.74M710.35M678.26M651.76M
Depreciation & Amortization34.54M54.18M107.67M69.54M85.22M
EBITDA48M65.19M108.82M153.92M184.36M
EBITDA Margin6.4%8.5%14.5%19.4%23.1%
Operating Income13.41M1.74M(27.01M)65.85M87.49M
Operating Margin1.8%0.2%-3.6%8.3%11.0%
Interest Income59K9.27M32.17M23.27M10.93M
Interest Expense23.64M34.24M56.73M52.92M42.61M
Other Income / Expenses(23.58M)(24.97M)(28.57M)(34.39M)(30.95M)
Income Before Tax(10.18M)(23.23M)(55.57M)31.46M56.54M
Pre-Tax Margin-1.4%-3.0%-7.4%4.0%7.1%
Income Tax Expense15.08M9.6M(46.7M)15.07M26.1M
Net Income(25.25M)(32.83M)(8.87M)16.39M30.44M
Net Margin-3.4%-4.3%-1.2%2.1%3.8%
EPS (Basic)(0.06)(0.08)(0.02)0.040.09
EPS (Diluted)(0.06)(0.08)(0.02)0.040.09
Weighted Avg Shares409.98M412.86M410.32M385.74M356.33M
Weighted Avg Shares (Diluted)409.98M412.86M410.32M392.17M356.97M

GoodRx Holdings, Inc.

NASDAQ:GDRX

Intrinsic Alpha fair value

Locked

Current Price

$3.36

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.